FilingReader Intelligence
CSPC subsidiary wins dupilumab biosimilar trial approval
August 19, 2025 at 08:21 AM UTC•By FilingReader AI
CSPC Innovation Pharmaceutical's subsidiary CSPC Megalith Biopharmaceutical received approval from China's National Medical Products Administration for clinical trials of its dupilumab biosimilar.
The biosimilar targets the same mechanism as Dupixent, a blockbuster treatment for moderate-to-severe atopic dermatitis. Domestic trials will commence soon.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
SZSE:300765•Shenzhen Stock Exchange
News Alerts
Get instant email alerts when CSPC Innovation Pharmaceutical publishes news
Free account required • Unsubscribe anytime